scout
News|Articles|May 2, 2024

Supplements and Featured Publications

  • Medical World News
  • Volume 1
  • Issue 1

Investigators Highlight Improvements in Immune and Endocrine Therapies for Breast Cancer

Author(s)OncLive Staff
Listen
0:00 / 0:00

Breast oncologists recap findings from the 2022 San Antonio Breast Cancer Symposium.

Breast oncologists recap findings from the 2022 San Antonio Breast Cancer Symposium. Sasha E. Stanton, MD, PhD, says that for patients
with hormone receptor–positive disease finding the best immunotherapeutic choice can present a challenge. Rupert Bartsch, MD, highlights findings from the phase 2 RIGHT Choice study (NCT03839823), which demonstrated promise with ribociclib (Kisqali) plus goserelin
acetate plus hormonal therapy among patients with advanced/metastatic disease. Erika P. Hamilton, MD, reviews exciting novel endocrine
therapies that may soon play a role.

TO WATCH, VISIT bit.ly/3ITTDtD.

Articles in this issue

Newsletter

Stay up to date on the most recent and practice-changing oncology data

Latest CME